Physician profile
Amy E Warner
NPI 1922166172
$4,266.70
in general payments reported to CMS, 2019-2025
26 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $352 · 2023: $1,588 · 2024: $966 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $456.70 | 2023-2025 | Ingrezza |
| Abbvie INC. | $342.55 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $315.32 | 2021-2024 | Lokelma, Farxiga |
| Scpharmaceuticals INC. | $256.37 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $253.99 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $232.24 | 2023-2024 | Rexulti |
| Viiv Healthcare Company | $228.21 | 2022-2024 | Dovato |
| Boston Scientific Corporation | $193.07 | 2023 | |
| Tris Pharma INC | $183.30 | 2025 | Dyanavel Xr |
| Grifols USA, LLC | $135.99 | 2023 | Prolastin-C Liquid |
| Astellas Pharma US INC | $128.93 | 2025 | Veozah |
| Amgen INC. | $128.21 | 2024 | Krystexxa |
| Gilead Sciences, INC. | $125.00 | 2023 | Descovy |
| Glaxosmithkline, LLC. | $124.98 | 2025 | |
| Alpha Cognition USA, INC. | $124.89 | 2025 | Zunveyl |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $123.92 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.64 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $120.56 | 2023 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.98 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $119.86 | 2025 | Zoryve |
| Impel Pharmaceuticals INC. | $110.32 | 2023 | Trudhesa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $109.91 | 2025 | |
| Exact Sciences Corporation | $82.94 | 2025 | The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $77.57 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $25.13 | 2023 | Spravato |
| Xeris Pharmaceuticals, INC. | $24.12 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.